risankizumab
Sign in to saveAlso known as BI 655066, BI-655066, Skyrizi
Risankizumab ( ), sold under the brand name Skyrizi ( ), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu
- Drug.target
- Interleukin 23A
- Drug.tradename
- Skyrizi
- Drug.MedlinePlus
- a619035
- Drug.DailyMedID
- Risankizumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AC18
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
via Wikipedia infobox
~3 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Adverse effects
- History
- Clinical trials
- Psoriasis
- References
- External lists
Risankizumab ( ), sold under the brand name Skyrizi ( ), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.
The most common side effects include upper respiratory infections (nose and throat infection)..
Excerpted from Wikipedia’s “risankizumab” article, available under the CC BY-SA 4.0 licence.